Trials Sponsors Conditions Drugs Pricing

Conditions

Multiple Myeloma

Outcome Measures

Primary Outcomes (2)

Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein.
Reporting of the relative amount of patients for whom such sdAb could be successfully obtained
Within 2 years after study completion
Amount of Paraprotein-targeting sdAbs Generated Per Patient
Absolute amount of unique sdAbs obtained per patient
Within 2 years after study completion

Study Arms (1)

Clinically Suspected or Pathologically Confirmed Multiple Myeloma.

OTHER

Patients with a clinically suspected or pathologically confirmed multiple myeloma.

Other: Blood sampling and bone marrow analysis

Interventions

Blood sampling and bone marrow analysisOther

Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)

Clinically Suspected or Pathologically Confirmed Multiple Myeloma.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Patients will only be included in the study if they meet all of the following criteria:
Patients who have given informed consent

Sponsors & Collaborators

Stichting tegen Kanker
Othercollaborator
Universitair Ziekenhuis Brussel
Otherlead

Study Sites (1)

UZ Brussel

Brussels, 1090, Belgium

MeSH Terms

Conditions

Multiple Myeloma

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative Disorders

Results Point of Contact

Title: Dr. Matthias D'Huyvetter
Organization: Vrije Universiteit Brussel

Study Officials

Marleen Keyaerts, MD
Universitair Ziekenhuis Brussel
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: No
Restrictive Agreement: No

Enrollment

10 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: OTHER
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 18, 2019

First Posted

May 21, 2019

Study Start

February 12, 2019

Actual (reported)

Primary Completion

sdAb-based TRNT of Multiple Myeloma: a Feasibility Study

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

Clinically Suspected or Pathologically Confirmed Multiple Myeloma.

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

Clinically Suspected or Pathologically Confirmed Multiple Myeloma.

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Documents

Locations